0000891293-19-000010.txt : 20190221 0000891293-19-000010.hdr.sgml : 20190221 20190221184602 ACCESSION NUMBER: 0000891293-19-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190219 FILED AS OF DATE: 20190221 DATE AS OF CHANGE: 20190221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 19623500 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2019-02-19 0 0000891293 CTI BIOPHARMA CORP ctic 0001276750 KIRSKE DAVID C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer Non-Qualified Stock Option (right to buy) 0.9489 2019-02-19 4 A 0 500000 0 A 2029-02-19 Common Stock 500000 500000 D 1/3 of the shares subject to the Option shall vest on the one year anniversary of February 19, 2019, and 1/3 of the shares shall vest annually thereafter on February 19, subject to Reporting Person continuing to be an employee or service provider on each date, such that the Option shall be fully vested on February 19, 2022. David H. Kirske 2019-02-19